3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1/2
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
123
Breast Neoplasms
103
Neoplasms
100
Leukemia, Myeloid, Acute
88
Melanoma
84
Multiple Myeloma
81
Neoplasm Metastasis
80
Recurrence
68
Ovarian Neoplasms
65
Prostatic Neoplasms
59
Lymphoma
59
Colorectal Neoplasms
58
Lymphoma, Non-Hodgkin
55
Leukemia
55
Pancreatic Neoplasms
50
Lung Neoplasms
47
Leukemia, Lymphocytic, Chronic, B-Cell
42
Myelodysplastic Syndromes
41
Carcinoma, Renal Cell
39
Squamous Cell Carcinoma of Head and Neck
38
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Glioblastoma
35
Lymphoma, Large B-Cell, Diffuse
34
Triple Negative Breast Neoplasms
33
Carcinoma, Hepatocellular
33
Stomach Neoplasms
29
Small Cell Lung Carcinoma
27
Lymphoma, Follicular
27
Brain Neoplasms
26
Lymphoma, Mantle-Cell
25
Interventions
pembrolizumab
1
enfortumab vedotin
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Terminated
×
Urethral Neoplasms
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA